Monograph Capital

Founded in 2021, Monograph Capital is a venture capital firm headquartered in San Francisco and London. The company invests in life sciences ventures focused on developing innovative therapeutics and related technology-enabled services.

Charles Conn

Co-Founder and Partner

Tim Funnell Ph.D

Co-Founder and Partner

Michael LaGatta JD

Partner and COO

Bonnie van Wilgenburg

Principal

Charlie Zhou

Associate

12 past transactions

Maxion Therapeutics

Series A in 2025
Maxion Therapeutics develops a novel platform to generate antibody-like therapeutics targeting ion channels and GPCR-driven diseases. The platform incorporates venom-derived knottins into antibody surfaces to create mixtures with optimized drug-like properties, enabling treatments for conditions such as chronic pain, autoimmune disorders, and heart disease. The company aims to deliver long-acting, safe, and effective medications against previously inaccessible targets.

Ouro Medicines

Series A in 2025
Ouroboros Medicines is a biotechnology company dedicated to immunology, focusing on treating chronic immune-mediated illnesses. It specializes in developing immune reset treatments, using a therapeutic platform that employs T cell engager antibodies to target and deplete specific pathogenic cells. This approach aims to provide extended remissions for patients, without the need for ongoing immunosuppression. The company's strength lies in its integration of scientific knowledge and proven track record in progressing cell-depleting treatments through clinical trials, supported by a robust pipeline.

Autobahn Therapeutics

Series C in 2024
Autobahn Therapeutics develops brain-targeting, small molecule therapies for central nervous system disorders. Its lead program ABX-002 is a thyroid hormone receptor beta agonist being developed as an adjunctive treatment for mood disorders, including major depressive disorder and bipolar depression. The company emphasizes precision tuning of CNS exposure, validated clinical and biologic targets, and biomarker-guided development across neuropsychiatry, neurodegeneration, and neuroinflammation to address high unmet medical needs and improve patient outcomes.

Nocion Therapeutics

Series B in 2024
Nocion Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, established in 2017. It specializes in developing innovative therapies known as "nocions," which are designed to treat conditions resulting from neurogenic inflammation. These therapies selectively target activated nociceptors, the sensory neurons responsible for pain perception, by utilizing small molecule charged sodium channel blockers. This targeted approach aims to provide robust and sustained relief from serious conditions such as cough, itch, pain, and inflammation, addressing the limitations of traditional small molecule anesthetics.

Sudo Biosciences

Series B in 2024
Sudo Biosciences is a biopharmaceutical company focused on developing innovative medicines targeting the tyrosine kinase 2 (TYK2) pseudokinase domain, which plays a critical role in immune-mediated inflammatory conditions. Its pipeline includes next-generation TYK2 inhibitors for treating multiple sclerosis and other neuroinflammatory diseases, as well as topical candidates for immune-mediated dermatologic conditions.

Sudo Biosciences

Series B in 2023
Sudo Biosciences is a biopharmaceutical company focused on developing innovative medicines targeting the tyrosine kinase 2 (TYK2) pseudokinase domain, which plays a critical role in immune-mediated inflammatory conditions. Its pipeline includes next-generation TYK2 inhibitors for treating multiple sclerosis and other neuroinflammatory diseases, as well as topical candidates for immune-mediated dermatologic conditions.

ODAIA

Series B in 2023
ODAIA is a technology company offering an AI-powered customer data platform for the life sciences industry. Its platform blends data analysis, process mining, and artificial intelligence to deliver goal-driven commercial insights and automate processes as a software-as-a-service. It supports personalized selling by helping pharmaceutical teams map customer journeys and optimize engagement to ensure therapeutics reach patients who need them.

Maxion Therapeutics

Series A in 2023
Maxion Therapeutics develops a novel platform to generate antibody-like therapeutics targeting ion channels and GPCR-driven diseases. The platform incorporates venom-derived knottins into antibody surfaces to create mixtures with optimized drug-like properties, enabling treatments for conditions such as chronic pain, autoimmune disorders, and heart disease. The company aims to deliver long-acting, safe, and effective medications against previously inaccessible targets.

RegASK

Series A in 2022
RegASK Pte. Ltd. is a RegTech company headquartered in Singapore, established in 2018. The firm specializes in developing an artificial intelligence-driven platform that assists businesses in managing regulatory compliance across various industries, including food, dietary supplements, cosmetics, personal care, and medical devices. The company's services encompass a wide range of regulatory needs, such as path-to-market, path-to-claim, product registration, and strategic guidance. RegASK's technology continuously monitors and reports updates on relevant regulations, providing clients with real-time alerts and insights into environmental, social, and governance (ESG) issues. This enables organizations to streamline their regulatory research processes, reducing time and costs while allowing them to concentrate on their core competencies.

HI-Bio

Series A in 2022
Human Immunology Biosciences is a biotechnology company dedicated to developing precision therapies for immune-mediated diseases, particularly autoimmune and inflammatory conditions. The company is known for its lead product, felzartamab, a fully human anti-CD38 monoclonal antibody that targets and depletes CD38+ cells, including plasma and natural killer cells. This mechanism has shown promise in improving clinical outcomes across a range of immune-mediated disorders. By focusing on transformative biotechnology-based treatments, Human Immunology Biosciences aims to enhance the quality of life for patients suffering from these challenging conditions.

MiroBio

Series B in 2022
MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on the development and manufacture of antibody modulators for immune cell receptors, targeting autoimmune diseases. Established in 2018, MiroBio leverages groundbreaking research from the University of Oxford to understand the communication and activation mechanisms of immune cells. The company's innovative platform aims to create antibodies that stimulate specific immune signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural processes, MiroBio seeks to provide significant therapeutic benefits for patients suffering from a range of autoimmune conditions, enabling clinicians to better manage and treat these diseases.

AviadoBio

Series A in 2021
AviadoBio focuses on developing transformative gene therapies for devastating neurodegenerative disorders such as frontotemporal dementia and amyotrophic lateral sclerosis. The company's platform combines proprietary technologies with a deep understanding of the brain to deliver effective treatments.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.